HDAC9 and plasma cell myeloma: Agents in the HDAC and proteasome inhibitor classes have achieved regulatory approval for hematologic malignancies (multiple myeloma and selected lymphomas) but not for solid tumors (Kambhampati & Wiita, 2020).